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Abstract
Study Design: Literature Review (Narrative)
Objective: To introduce the number one research priority for Degenerative Cervical Myelopathy (DCM): Raising Awareness.
Methods: Raising awareness has been recognized by AO Spine RECODE-DCM as the number one research priority. This
article reviews the evidence that awareness is low, the potential drivers, and why this must be addressed. Case studies of success
from other diseases are also reviewed, drawing potential parallels and opportunities for DCM.
Results: DCM may affect as many as 1 in 50 adults, yet few will receive a diagnosis and those that do will wait many years for it.
This leads to poorer outcomes from surgery and greater disability. DCM is rarely featured in healthcare professional training
programs and has received relatively little research funding (<2% of Amyotrophic Lateral Sclerosis or Multiple Sclerosis over the
last 25 years). The transformation of stroke and acute coronary syndrome services, from a position of best supportive care with
occasional surgery over 50 years ago, to avoidable disability today, represents transferable examples of success and potential
opportunities for DCM. Central to this is raising awareness.
Conclusion: Despite the devastating burden on the patient, recognition across research, clinical practice, and healthcare policy
are limited. DCM represents a signiﬁcant unmet need that must become an international public health priority.
Keywords
cervical, myelopathy, spondylosis, spondylotic, stenosis, disc herniation, ossiﬁcation posterior longitudinal ligament,
degenerative cervical myelopathy, disability, prioritization, research prioritization, review, policy

Introduction
Degenerative Cervical Myelopathy (DCM) is an allencompassing term for neural dysfunction secondary to cervical cord dysfunction caused by processes of a degenerative,
arthritic, and/or congenital nature.1-3 It is estimated to affect up
to 2% of adults4 and is often associated with signiﬁcant
disability.5 DCM can cause a wide range of symptoms, including pain, imbalance and difﬁculty walking, loss of dexterity, sensory loss, bowel or bladder dysfunction, and in
extreme circumstances total paralysis.2
Early diagnosis and surgical treatment can be beneﬁcial.6
However, many people with DCM are unfortunately not
diagnosed in a timely manner, and despite appropriate yet
delayed treatment at the time of their diagnosis, these individuals may have substantial residual neurological
dysfunction.7
The persistent neurologic dysfunction has life-long implications, with dependency, unemployment, and mental
health difﬁculties prevalent.7,8 A comparison of SF-36 scores
of people with chronic disease found that individuals with
DCM have amongst the lowest quality of life scores.8
Therefore, efforts to address and improve DCM patients’
quality of life should be a critical priority.
AO Spine RECODE-DCM (aospine.org/recode) REsearch
objectives and COmmon Data Elements for DCM is an international consensus project which aims to accelerate
knowledge discovery that can improve outcomes, by developing a set of research tools.9 These include a James Lind
Alliance research priority setting partnership, which brought
together both individuals living and working with DCM, to
establish the most important unanswered questions. Research

prioritization aims to catalyze progress by consolidating resources on key knowledge gaps. The Number one priority
identiﬁed was raising awareness amongst the public, health
professionals, and funding agencies.
This article aims to contextualize the signiﬁcance of this
question, to illustrate the evidence that awareness is low, the
potential drivers, and why this must be addressed. Finally, we
will consider case studies of success from other diseases,
drawing potential parallels and opportunities for DCM, some
of which are already being considered.

What is the Evidence that Awareness of DCM is Low?
The lack of awareness for DCM can be demonstrated through
the misconceptions that challenge diagnostic and treatment
practice, but also perhaps the makeup and focus of DCM
research, and relative lack of investment. It is strongly suspected that DCM is signiﬁcantly under-diagnosed.2 In one
series of patients presenting with a neck of femur fracture (N =
159), 18% were identiﬁed to have undiagnosed DCM.10 In
another series of patients presenting to a neurology clinic with
spastic tetraparesis (N = 585), DCM was 2.5 times more
common than Multiple Sclerosis.11 Moreover, a recent metaanalysis of MRI imaging of healthy volunteers (N = 3786,
Mean Age of studies 40–66 years, with one additional study of
teenagers) demonstrated that 24.2% of individuals had visualized spinal cord compression, and some series included
current clinical assessment (N = 1202), providing a pooledestimate of DCM of 2.3%.4 This estimate of DCM in the
general population is further supported by longitudinal studies
of asymptomatic radiographic spinal cord compression, which
noted that approximately 10% of these asymptomatic spinal
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cord compression patients progress to develop a clinical
myelopathy overtime (range 2–12) years.12-14
The symptoms of DCM often mimic other pathological
conditions, such as Carpal Tunnel Syndrome, which frequently leads to delays and misdiagnosis15,16: A survey of the
Myelopathy.org community identiﬁed on average persons
with cervical myelopathy wait 2–3 years, with over a third
longer than 5 years, from onset of symptoms to diagnosis.7
Research activity is also a potential surrogate of disease
awareness. Dimensions Plus (Dimensions.ai, London, UK) is
a proprietary bibliometric platform, indexing both published
literature and research funding.17 A comparative search of
DCM, multiple sclerosis, amyotrophic lateral sclerosis, and
spinal cord injury demonstrates that since 2011, DCM has
received <2% of grant funding awarded compared to these
other diseases (Figure 1). Whilst there are limitations to this
comparison, which should not be used to suggest these other
diseases are less deserving, it illustrates a signiﬁcant awareness gap across the broader research environment. Certainly,
given the importance of DCM to public health, a strong argument exists for funding initiatives to address this important
health issue.
The care pathway for DCM often involves numerous
specialties.16 This is a testament to the challenges for diagnosis but also signiﬁes the diverse and life-long disabilities
that can result, even after surgical treatment. To date, these
perspectives have not been well represented in DCM research,18 with the ﬁeld predominantly led by spinal surgeons.19 In fact between 1995 and 2015, 79% of primary
clinical studies, exclusively evaluating DCM in humans,
evaluated cohorts undergoing surgical treatment and 55.7%
speciﬁcally evaluated a surgical technique or approach.19
Whilst this correlates with advances in the evidence guiding surgical treatment,20,21 it underrepresents the diverse issues which also exist before and after surgery, identiﬁed as
priorities in this multi-stakeholder process.9,22
There are often challenges for research advances to successfully enter clinical practice.23 Over the last decade, research has noted that DCM features captured using
conventional MRI, such as the degree of compression and
spinal cord signal changes, are only weakly correlated with
disease severity.4,24-26 Instead, management of DCM is guided
by clinical assessment of functional impairment using tools
such as the modiﬁed Japanese Orthopedic association score
(mJOA).20 The 2017 International Consensus guidelines
recommend surgical intervention in those patients with
moderate to severe impairment, or those with mild disease in
the presence of cord compression and symptomatic radiculopathy, with observation and non-operative measures considered for patients with mild disease. However, despite the
publication of these guidelines, a signiﬁcant heterogeneity
exists in the management of DCM patients. A regional audit in
the UK demonstrated that cervical MRI features of spinal cord
compression was the predominant determinant of surgical vs
non-operative management rather than the level of functional
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Figure 1. Global Grant Funding for Research into Multiple
Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Traumatic Spinal
Cord Injury, and Degenerative Cervical Myelopathy DCM 2011–
2020. Data is extracted from Dimensions Plus (Dimensions.ai, United
Kingdom), using search terms “Multiple Sclerosis,” “Amyotrophic
Lateral Sclerosis,” “Spinal Cord Injury,” and “Degenerative Cervical
Myelopathy” or “Cervical Spondylotic Myelopathy,” searched
February 10th 2020.

impairment.27 This exempliﬁes the fact that even spine specialists may not be employing the most up-to-date evidencebased practice.

Why is Awareness Low?
A fundamental problem is that there is a perception that
prevalence of DCM is rare.28,29 This may have arisen from
early difﬁculties in diagnosing spinal cord compression,
without advanced imaging such as MRI. However, this legacy
remains, and whilst epidemiological studies in DCM still
quote pooled prevalence estimates of 4-6/100,000, this data is
a recognized under-estimate, relying on operative incidence,
and unable to account for under diagnosis.30-32 The aforementioned 2.3% for the entire population, albeit indirect, is a
more likely the most realistic estimate.2,4
Characterizing the epidemiology of DCM is also hampered
by imprecise coding. DCM is referred to by numerous terms:
14 different terms were identiﬁed in our recent search of
EMBASE, MEDLINE, and Clinicaltrials.gov. This inconsistency is also reﬂected within literature indexing and WHO
ICD (International Classiﬁcation of Disease) Coding, a fundamental component of epidemiology study.32 For example, a
recent review of spinal surgery for degenerative cervical spine
disease in Finland used a combination of 18 different ICD
codes to identify cases of DCM, with acknowledged speciﬁcity issues.33 Efforts to raise awareness of a condition can
only be diluted if multiple terms are being used.
Regardless of the terminology, DCM features poorly in
medical student and general professional education programs. An evaluation of curricula and training resources for
UK Medical Schools and Primary Care Training Pathways
identiﬁed that DCM was rarely, if ever, speciﬁed.34 In
contrast, cauda equina syndrome, a much rarer disorder than
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DCM but well-publicized condition (likely owing to its
medicolegal ramiﬁcations) featured more often. Despite the
low representation in training, clinical knowledge as evaluated using multiple choice questions in an electronic
question bank, was good (Figure 2).34 Speciﬁcally, DCM
questions were completed 127,457 times, by medical students or doctors preparing at 3 different stages: Entry into
UK clinical practice (deﬁned as medical school exit exams or
the PLAB, a UK speciﬁc assessment of competency for
professionals trained overseas), entry into primary care
training or exit from primary care training. At each stage,
users were more likely to answer DCM questions correctly,
than the database average as a whole or for other neurological
diseases.34
Whilst multiple-choice examination is not the same as
clinical practice, associations between performance have
been linked to in-practice indicators, such as clinical
performance35,36 or medical board disciplinary actions.37
The aforementioned ﬁndings therefore raise 2 additional
questions. Firstly, is clinical education and current knowledge providing the right information for early detection of
DCM and secondly, whilst professionals may recognize key
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neurological concerns on paper, do they raise the index of
suspicion from clinical histories or examinations.
The presenting symptoms and duration of symptoms of
DCM are often highly variable between individuals. The early
features of DCM are poorly characterized, with most descriptions informed by advanced disease.29 The recent imaging series by Martin et al38 (2018) suggests that spinal cord
damage, as identiﬁed using quantitative MRI techniques
occurs prior to symptom onset or detection on conventional
examination ﬁndings. Conventional diagnostic teaching has
focused on neuromuscular features of the upper and lower
limb29,39 but many other symptoms have also been associated
with DCM, including headaches, hypertension, and respiratory dysfunction.40 Their signiﬁcance for diagnosis and early
detection are unclear but unconventional symptoms such as
chest pain have been shown to be potentially predictive of a
distinguishing DCM from other related pathology in one
study.41 Taken together, this suggests a more complete assessment of the disability in DCM, may be important to help
distinguish DCM from common differentials29; for example,
neck pain is reported by people with DCM, but has a population prevalence of ∼15%.28

Figure 2. Knowledge of DCM, compared to Multiple Sclerosis, General Neurology, Cauda Equina Syndrome, and Diabetes Mellitus amongst
UK medical professions revising for entry into UK clinical practice (medical school exit exams or PLAB Professional And Linguistic
Assessment Board—a UK speciﬁc assessment of competency for professionals trained overseas), entry into primary care training (SRA—
Speciality Recruitment Assessment), or exit from primary care training (MRCGP—Membership Royal College of General Practitioners)
(Reproduced from Ref. 34). Performance is expressed as relative to overall question bank mean. * denotes no questions included in question
bank at this training stage.
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Physical examination is a key part of a neurological assessment of DCM. However, it has been recognized that in
general, medical professionals are insecure about dealing with
neurological disease.42 This aversion was coined “Neurophobia” by Dr Ralph Jozefowicz,43 who hypothesized that the
perceived complexity of neurological disease, led to disengagement in learning and training and less proﬁciency as
professionals. A number of professional surveys have since
demonstrated this sentiment,44-46 with many professionals
preferring to refer on to a “specialist”. This will inevitably add
further delay in the diagnostic pathway, increasing time between presentation, diagnosis, and treatment. The neurological examination can be challenging, even in experienced
hands, with signs often in fact incidental.47,48 Specialists often
tailor their assessment to the speciﬁc neurological differential,
without consensus on a minimum and standard assessment.42
In a retrospective study of patients presenting with DCM to a
single center, Hilton et al (2018) demonstrated the assessment
was different between primary care, secondary care, and spinal
surgery49; in particular primary care focusing on peripheral
limb strength, whereas secondary care and spinal surgery
long-tract signs.
A solution to circumvent this would be a deﬁned screening
algorithm (46). Cauda Equina Syndrome (CES) has a welldeﬁned list of “red ﬂags” in order to prompt urgent MRI
imaging. Whilst individually, or even in combination, these
symptoms have a low predictive value for CES,50,51 they are
better known across all healthcare professionals and used to
triage immediate imaging.34
Beyond symptoms and examination ﬁndings, MRI remains
an important component of diagnosis. Unfortunately, access to
MRI is challenging in many healthcare settings (49). In the
UK, most primary care physicians are unable to access MRI
directly, and instead patients must pass to a secondary care
provider ﬁrst, often waiting months for this study.16 However
access to MRI alone is not a panacea as MRI ﬁndings are not
speciﬁc for DCM: visualized compression on MRI is a diagnostic hallmark, but more commonly incidental and in the
setting of no symptoms; therefore diagnosis requires a
combination of correlating symptoms, examination ﬁndings,
and imaging features. However most non-specialists rely on
qualitative reports of MRI, and the subjective language including “touching” or “indenting” the spinal cord can be
falsely reassuring.52 Improved access to MRI will therefore
need to be complimented by education or a standardized
reporting style (52).

Why Must Awareness Improve?
Optimizing the timing of surgical treatment is fundamental to
maximizing its beneﬁts. Surgery to remove spinal cord
compression is the mainstay of present treatment. While
typically patients sustain some improvement, the recovery,
however, is rarely complete as the spinal cord has a limited
intrinsic capacity for recovery and residual disability is
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considered to reﬂect irreversible damage.1 Secondary analysis
of trial data evaluating surgical intervention for DCM has
demonstrated that time to treatment, speciﬁcally within 4–
6 months of symptom onset, is an important positive predictor
for greater recovery.6 However, this starkly contrasts the
frequent delays experienced in practice and highlights the
signiﬁcance of achieving early diagnosis.7,16
To complicate matters further the natural history of
DCM is poorly understood, with a large proportion of spinal
cord compression initially asymptomatic or minimally
symptomatic.53 Identifying which individuals are at high risk
for the development of DCM or progression would allow a
personalized medicine approach to early diagnosis and intervention allowing for safer application of surgery with
improved outcomes.
This critical concept of optimizing the timing of surgical
treatment is reﬂected throughout the top 10 research priorities identiﬁed during the AO Spine RECODE-DCM
priority setting process; raising awareness to expedite diagnosis (Number 1), developing sensitive assessment tools
to identify progression (Number 2), understand the natural
history (Number 3), and individualizing surgical care
(Number 10). These knowledge gaps illustrate that in order
to improve outcomes, awareness must improve not just to
increase early diagnosis, but more broadly: It is clear that a
multi-disciplinary approach to managing DCM represents
an optimal approach,54 and this extends throughout the
lifetime of someone with DCM. Awareness therefore needs
to permeate DCM care specialties, but also more broadly, to
entice both research funding and clinical researchers into
this ﬁeld.
Raising awareness can be considered fundamental to improving outcomes in DCM.

What Could Success Look Like? Perspectives From
Other Diseases’
The management and outcomes of acute myocardial Infarction
(MI) and cerebrovascular accident (CVA) have dramatically
changed over the last 50 years.55-57 In the 1950s, care was
supportive, often simply managed at home, whereas today
many individuals will be left without disability or recurrent
episodes.58
Success has resulted from a comprehensive and multifaceted approach, advancing both understanding but also
awareness. Key milestones for care include the concentration
of care into specialist units (e.g., Coronary Care or Stroke
Units),59 development of clear referral pathways, including
triage or screening tools (e.g., FAST—Facial Droop, Arm
Weakness, Speech Difﬁculty, Time to call an ambulance—for
CVA),60,61 advances in and access to diagnostic tools (e.g., CT
Head62 or Cardiac Enzymes63), signiﬁcant professional but
also general public awareness campaigns,61,64-66 and of course
signiﬁcant advances in treatment options beyond open heart
surgery (e.g., Anti-Platelet medication and Interventional
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Radiology), including preventive medicine67,68 and symptomatic treatments.
Whilst these diseases may seem unrelated, particularly
given their comparative acuity and risk of mortality, they hold
major parallels with DCM: these are diseases of adulthood,
where time to treatment is a determinant of outcome. Treatment
is delivered by tertiary services, relying on non-specialists
to suspect, diagnose, and initially manage patients. The
implications for sub-optimal management are signiﬁcant
and life-altering, with all patients having some degree of
life-long treatment and care requirements, and potentially
recurrent disease. Furthermore, the current standards of
DCM care; a common and disabling condition, treated in
some cases with surgery and mostly managed by nonspecialists, reﬂects the historical standards of care for MI
and CVA.

One of the particularly interesting aspects of both MI and
CVA care today, is the recognition that these conditions
are syndromes, with a requirement for care to be tailored
based on a range of demographic and diagnostic data. For
example, for CVA, in simplistic terms, care has evolved from
supportive only, to timely/reactive (e.g.,, Anti-Platelet/
Interventional Radiology), to also pre-emptive detection
(e.g.,, Transient Ischemic Attack emergency clinics69) and
preventative treatments (e.g.,, Carotid Endarterectomy and/
or Anticoagulation).56,57,70 Within these treatment arms,
there is a stratiﬁcation of disease, to ensure that care is
optimized for that individual scenario. One can foresee a
similar future for DCM, although substantial evidence gaps
need to be overcome.53,71
It is difﬁcult to tease out the key individual drivers for
these successes, but progress has likely beneﬁted from a

Table 1. Gap Analysis of disease characteristics and drivers of progress between Myocardial Infarction (MI), Cerebrovascular Accident
(CVA), and DCM. Variables (Column 1) are author selected, and their signiﬁcance per disease listed. $ Prevalence taken as cases of Acute
Myocardial Infarction or First Time Ischemic Cerebrovascular Accident and £ At risk population as cases of Cardiovascular Disease from
Global Burden of Disease Report 2015, and expressed as a proportion of global population in 2015.81 DALY: All age, Disability Adjusted Life
Years from Global Burden of Disease Report 2015.82

Disease characteristics
Prevalence (%)
At risk population (%)
Mortality
Morbidity
Time to treatment
Management characteristics
Screening tools/Red ﬂags
Triage tools
Diagnostic algorithms
Specialist care units
Rehabilitation pathways
Clinical practice guidelines
Preventative medicine/Early
detection
Screening
Additional drivers
Lay terminology
Advocacy organizations
Public education campaigns
Commercial investment/Interest
Financially incentivized care
delivery targets “payment by
results”
Health-economic argument for
management and research
Supra specialization

Degenerative Cervical
Myelopathy

Myocardial Infarction

Cerebrovascular Accident

1.1%$81
5.5%£81
1 in 4 deaths globally82
High82 45,208,500 DALY
(43 1502 to 47 3868)
Well documented85 and
global priority

.8%$81

Yes87
Yes87
Yes87
“Coronary Care Unit”

Yes88
Yes89
Yes
“Acute Stroke Unit”

Yes
Many

Yes
Many

No
mJOA recently introduced
No
No Few qualify for specialist
Spinal Cord Injury providers
No90
Treatment guidelines20

Yes

Yes

No

“Heart Attack”
Many
Many66
High91
Yes92

“Stroke”
Many
Many61
High91
Yes93

None
One
None
Low91
No

Strong94

Strong95

Yes, sub-specialisation
within cardiology

High82 164 0204 DALY (159 6213 to
169 0882)
Well documented86 and global priority

Unknown estimated 2.4%4
Unknown estimated 24%4
Unknown, presumed low83,84
Unknown, presumed high
<5% Full Recovery5
Recently evidenced, not yet
adopted

Limited Cost-Effectiveness of
Surgery (North America)96,97
Yes, stroke medicine now a distinct specialty No
and training pathway in many countries
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strong health-economic argument, signiﬁcant research investment, including industrial and multi-disciplinary involvement, numerous and prominent advocacy groups,
public and professional education, super-specialization and
regular representation in national healthcare policy including
legislated care targets. These drivers are here author deﬁned,
but as highlighted in Table 1 are mostly missing and/or
unknown in DCM.

What is Being Done to Address this in DCM?
Guidelines are an essential part of changing clinical practice.23 Guidelines for the management of DCM were developed by AO Spine in 2017,20 these have since been
endorsed and extended with recommendations by the World
Federation of Neurosurgeons Spine Committee.72-76 These
primarily focus on the treatment of DCM, and not the
detection or long-term management. The AO Spine
guidelines introduced the use of the mJOA assessment tool,
recognizing that different degrees of functional impairment
appear to have a different disease trajectory.20,77 Although
not suitable for disease screening, this is the ﬁrst example of
a decision algorithm based on an assessment tool in DCM.
However, the mJOA does have certain limitations and a
degree of inter-rater reliability error, which should always
be considered in patients who have “borderline” assessment
scores.78
In the UK, the National Institute for Health and Care
Excellence (NICE) has attempted to address early detection
challenges with guidance for management of common neurological symptoms.79 The guidance has received criticism in
some quarters,80 largely based on its breadth (eg, cervical
myelopathy is poorly covered) but also the inconsistency of
symptom-based categorization (eg, “slowly progressive limb
weakness”) and disease-based categorization (eg, Bell’s
Palsy), with the latter too reliant on professional knowledge
which contrasts the aforementioned concerns. It is too early to
evaluate the impact of such tools, but they are an important
ﬁrst step.
AO Spine RECODE-DCM has additional objectives. This
includes the consensus selection of the condition name and its
deﬁnition.9 This will hopefully directly support efforts to
ensure consistent messaging, important for awareness. It is of
note in the aforementioned success stories, both MI and CVA
have ubiquitous and lay terms; “heart attack” and “stroke”.
This may be of signiﬁcance for public awareness. However
additionally, the priorities identiﬁed here also target key
knowledge gaps to support awareness.
Myelopathy.org, a charity for DCM, was formed in 2017. It
is the ﬁrst, and so far, only charity speciﬁcally for DCM.
Whilst there are many spinal cord injury charities, the majority
have a focused remit on acute, traumatic injury and have
considered DCM outside of this. Myelopathy.org, with a
growing community of people living with DCM and also
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professionals, will hopefully serve as a focal point to advocate
effectively for DCM.

Conclusions
DCM is a common and progressively disabling condition, for
which awareness by the public, professionals, and funding
agencies is low. Improving awareness could signiﬁcantly
improve outcomes, by ensuring timely diagnosis and treatment and minimizing chronic neurological disability. This was
determined to be the number one research priority identiﬁed
by AO Spine RECODE-DCM initiative. Further enhanced
research and awareness of DCM is an urgent public health
priority and a call to action is required!
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